First Patient Enrolled in US Phase 2 Trial of Akeso’s Ligufalimab and Azacitidine Combo for Myelodysplastic Syndrome.

Genmab A/S revealed that it will take over full responsibilities for both the ongoing development and possible commercialization of acasunlimab.

Rezolute Receives FDA Approval for Phase 3 IND Study of RZ358 for Hypoglycemia Caused by Tumor-Induced Hyperinsulinism.

Aug 8th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Imbrium Therapeutics L.P., has filed an Investigational New Drug Application with the U.S. Food and Drug Administration to assess the use of sunobinop for potentially treating moderate to severe alcohol use disorder.

With the completion of this acquisition, RayzeBio has brought BMS a promising pipeline of radiotherapeutic drugs, including its key project RYZ101 (225Ac-DOTATATE).

Bayer Reveals Phase III Study Results: FINEARTS-HF Achieves Key Goal for KERENDIA® (finerenone) in Heart Failure Patients with Mildly Reduced or Normal Ejection Fraction.

Johnson & Johnson has halted the development of their co-created anti-epileptic drug, ADX71149 (JNJ-40411813), with Addex Therapeutics after analyzing Phase 2 clinical data.

Repotrectinib, marketed under the brand name Augtyro, was FDA approved on November 15, 2023.

Innovent and SanegeneBio Announce Initial Dosing of Participant in Early-Stage Trial of IBI3016 (AGT siRNA).

DefenCath was approved by the U.S. Food and Drug Administration on November 15, 2023.

The paper discusses the identification of a novel negative allosteric modulator of the µ-opioid receptor (µOR) through screening with a DNA-encoded small molecule library.